HPV	B-OG
-	I-OG
16	I-OG
virions	O
can	O
remain	O
infectious	O
for	O
2	O
weeks	O
on	O
senescent	O
cells	O
but	O
require	O
cell	O
cycle	O
re	O
-	O
activation	O
to	O
allow	O
virus	B-OG
entry	O

Successful	O
infection	B-DS
with	O
Human	B-OG
Papillomaviruses	I-OG
requires	O
mitosis	O
,	O
when	O
incoming	O
viral	O
genomes	O
gain	O
access	O
to	O
nuclear	O
components	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
how	O
long	O
HPV	B-OG
particles	O
can	O
remain	O
infectious	O
in	O
non	O
-	O
dividing	O
cells	O
or	O
in	O
which	O
cellular	O
compartments	O
these	O
viruses	B-OG
may	O
reside	O
.	O

To	O
investigate	O
these	O
questions	O
we	O
have	O
used	O
BJ	O
cells	O
as	O
a	O
reversible	O
model	O
of	O
senescence	O
and	O
show	O
that	O
HPV	B-OG
-	I-OG
16	I-OG
can	O
only	O
infect	O
early	O
-	O
passage	O
proliferating	O
cells	O
.	O

Late	O
-	O
passage	O
senescent	O
cells	O
are	O
resistant	O
to	O
HPV	B-DS
infection	I-DS
,	O
but	O
this	O
can	O
be	O
reversed	O
by	O
inducing	O
cell	O
cycle	O
re	O
-	O
entry	O
with	O
a	O
p53	B-GP
siRNA	O
.	O

In	O
senescent	O
cells	O
we	O
find	O
that	O
efficient	O
virus	B-OG
entry	O
can	O
be	O
attained	O
upon	O
cell	O
cycle	O
re	O
-	O
entry	O
16	O
days	O
after	O
infection	B-DS
,	O
demonstrating	O
that	O
HPV	B-OG
can	O
persist	O
for	O
2	O
weeks	O
prior	O
to	O
induction	O
of	O
mitosis	O
.	O

However	O
,	O
exposing	O
cells	O
to	O
anti	O
-	O
HPV	B-OG
-	I-OG
16	I-OG
L1	B-GP
neutralising	O
antibody	B-GP
blocks	O
infection	B-DS
at	O
these	O
late	O
time	O
points	O
,	O
suggesting	O
that	O
the	O
virions	O
reside	O
near	O
the	O
cell	O
surface	O
.	O

Indeed	O
,	O
immunofluorescence	O
analysis	O
shows	O
that	O
virions	O
accumulate	O
on	O
the	O
cell	O
surface	O
of	O
senescent	O
cells	O
and	O
only	O
enter	O
endocytic	O
vesicles	O
upon	O
stimulation	O
with	O
p53	B-GP
siRNA	O
.	O

These	O
results	O
demonstrate	O
that	O
HPV	B-OG
-	I-OG
16	I-OG
virions	O
can	O
remain	O
viable	O
on	O
a	O
non	O
-	O
dividing	O
cell	O
for	O
extended	O
periods	O
of	O
time	O
,	O
but	O
are	O
nonetheless	O
vulnerable	O
to	O
antibody	B-GP
-	O
induced	O
neutralisation	O
throughout	O
.	O

Introduction	O

Human	B-OG
Papillomaviruses	I-OG
(	O
HPVs	B-OG
)	O
are	O
major	O
human	B-OG
pathogens	O
and	O
the	O
causative	O
agents	O
of	O
a	O
number	O
of	O
important	O
human	B-OG
malignancies	O
,	O
with	O
cervical	B-DS
cancer	I-DS
being	O
the	O
most	O
important1	O
,	O
2	O
.	O

The	O
viruses	B-OG
replicate	O
in	O
differentiating	O
epithelia	O
,	O
where	O
the	O
virus	B-OG
initially	O
gains	O
access	O
to	O
the	O
basal	O
cell	O
compartment	O
,	O
which	O
is	O
thought	O
to	O
occur	O
through	O
microtraumas	O
in	O
the	O
skin	O
.	O

Once	O
infected	O
,	O
the	O
basal	O
keratinocyte	O
begins	O
to	O
differentiate	O
and	O
the	O
combined	O
action	O
of	O
the	O
viral	B-GP
oncoproteins	I-GP
,	O
E6	B-GP
and	O
E7	B-GP
,	O
promotes	O
cell	O
cycle	O
entry	O
and	O
replication	O
of	O
the	O
viral	O
genomes	O
.	O

Ultimately	O
this	O
process	O
results	O
in	O
the	O
production	O
of	O
new	O
infectious	O
virus	B-OG
particles	O
in	O
the	O
upper	O
terminally	O
-	O
differentiated	O
layers	O
of	O
the	O
skin3	O
,	O
4	O
.	O

In	O
rare	O
cases	O
this	O
infectious	O
cycle	O
is	O
perturbed	O
,	O
and	O
over	O
a	O
number	O
of	O
years	O
malignancies	O
can	O
subsequently	O
arise	O
.	O

The	O
viral	O
capsid	O
contains	O
the	O
double	O
stranded	O
viral	O
genome	O
of	O
approximately	O
8	O
kb	O
,	O
which	O
is	O
enclosed	O
by	O
the	O
viral	B-GP
coat	I-GP
proteins	I-GP
L1	I-GP
and	O
L25	O
,	O
6	O
.	O

Whilst	O
both	O
proteins	O
play	O
essential	O
functions	O
in	O
capsid	O
assembly	O
and	O
virus	B-OG
entry	O
,	O
the	O
viral	B-GP
L2	I-GP
protein	I-GP
appears	O
to	O
be	O
the	O
most	O
important	O
for	O
ensuring	O
delivery	O
of	O
the	O
viral	O
genome	O
to	O
the	O
infected	O
cell	O
nucleus	O
,	O
where	O
viral	O
gene	O
expression	O
can	O
initiate7	O
,	O
8	O
.	O

The	O
whole	O
process	O
of	O
virus	B-DS
infection	I-DS
involves	O
multiple	O
steps	O
.	O

After	O
the	O
initial	O
attachment	O
of	O
incoming	O
virions	O
to	O
the	O
extracellular	O
matrix9	O
,	O
10	O
,	O
there	O
is	O
a	O
structural	O
alteration	O
to	O
the	O
viral	O
capsid	O
,	O
which	O
allows	O
binding	O
to	O
the	O
target	O
cell	O
and	O
subsequent	O
endocytic	O
uptake11	O
,	O
12	O
.	O

During	O
the	O
process	O
of	O
endocytic	O
maturation	O
and	O
acidification	O
the	O
capsid	O
begins	O
to	O
disassemble	O
,	O
and	O
at	O
some	O
point	O
in	O
this	O
process	O
the	O
L2	B-GP
proteins	O
become	O
partially	O
exposed	O
to	O
the	O
cytoplasmic	O
side	O
of	O
the	O
endocytic	O
vesicle13	O
,	O
14	O
.	O

This	O
exposure	O
of	O
L2	B-GP
plays	O
a	O
critical	O
role	O
in	O
recruiting	O
different	O
components	O
of	O
the	O
endocytic	O
cargo	O
sorting	O
machinery	O
,	O
which	O
includes	O
components	O
of	O
the	O
retromer	O
complex15	O
,	O
16	O
and	O
members	O
of	O
the	O
sorting	O
nexin	B-GP
protein	O
family17	O
,	O
18	O
.	O

Components	O
of	O
the	O
ESCRT	O
machinery	O
also	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
these	O
early	O
steps	O
of	O
infectious	O
entry19	O
–	O
21	O
and	O
eventually	O
,	O
through	O
the	O
action	O
of	O
cyclophilins	B-GP
,	O
the	O
L1	B-GP
protein	O
becomes	O
largely	O
dissociated	O
from	O
the	O
L2	B-GP
/	O
DNA	O
complex	O
and	O
is	O
processed	O
to	O
the	O
lysosomal	O
compartments	O
and	O
degraded22	O
,	O
whilst	O
the	O
L2	B-GP
/	O
DNA	O
complex	O
is	O
trafficked	O
to	O
the	O
trans	O
-	O
Golgi	O
network23	O
.	O

Only	O
upon	O
the	O
initiation	O
of	O
mitosis	O
and	O
nuclear	O
envelope	O
breakdown	O
does	O
the	O
L2	B-GP
/	O
DNA	O
complex	O
,	O
accompanied	O
by	O
a	O
small	O
amount	O
of	O
residual	O
L1	B-GP
,	O
then	O
gain	O
access	O
to	O
the	O
nucleus	O
where	O
the	O
viral	O
genome	O
ultimately	O
resides	O
at	O
PML	B-GP
oncogenic	O
domains	O
(	O
PODs	O
)	O
24	O
–	O
26	O
.	O

Viral	O
gene	O
expression	O
is	O
believed	O
to	O
initiate	O
at	O
these	O
domains	O
and	O
the	O
onset	O
of	O
a	O
new	O
round	O
of	O
viral	O
genome	O
amplification	O
and	O
viral	O
production	O
proceeds7	O
,	O
8	O
.	O

This	O
whole	O
entry	O
process	O
is	O
thought	O
to	O
be	O
rather	O
slow	O
,	O
often	O
taking	O
many	O
hours	O
,	O
although	O
if	O
infection	B-DS
occurs	O
at	O
a	O
point	O
when	O
the	O
cells	O
are	O
about	O
to	O
divide	O
then	O
entry	O
into	O
the	O
nucleus	O
can	O
be	O
much	O
faster27	O
.	O

Virus	B-OG
uptake	O
itself	O
is	O
also	O
believed	O
to	O
be	O
dependent	O
upon	O
growth	O
factor	O
signalling	O
,	O
and	O
there	O
is	O
some	O
evidence	O
to	O
suggest	O
that	O
virus	B-OG
entry	O
may	O
in	O
part	O
be	O
linked	O
to	O
growth	B-GP
factor	I-GP
receptor	I-GP
internalisation	O
,	O
suggesting	O
that	O
there	O
is	O
preferential	O
entry	O
of	O
the	O
virus	B-OG
into	O
proliferating	O
cells28	O
,	O
29	O
.	O

Nonetheless	O
a	O
critical	O
step	O
in	O
this	O
whole	O
pathway	O
is	O
the	O
initiation	O
of	O
mitosis	O
,	O
without	O
which	O
the	O
virus	B-OG
cannot	O
gain	O
access	O
to	O
the	O
nucleus	O
and	O
the	O
infection	B-DS
fails24	O
,	O
25	O
.	O

Whilst	O
HPV	B-OG
virions	O
are	O
known	O
to	O
be	O
quite	O
resilient	O
,	O
there	O
is	O
very	O
little	O
information	O
on	O
how	O
long	O
they	O
can	O
remain	O
infectious	O
once	O
exposed	O
to	O
their	O
target	O
cells	O
,	O
or	O
for	O
how	O
long	O
,	O
or	O
where	O
,	O
such	O
viruses	B-OG
might	O
reside	O
in	O
a	O
cell	O
that	O
is	O
not	O
undergoing	O
mitosis	O
.	O

In	O
order	O
to	O
begin	O
to	O
provide	O
some	O
answers	O
to	O
these	O
questions	O
we	O
have	O
made	O
use	O
of	O
a	O
model	O
of	O
reversible	O
replicative	O
cellular	O
senescence	O
.	O

BJ	O
cells	O
are	O
fibroblasts	O
that	O
undergo	O
replicative	O
senescence	O
following	O
extended	O
periods	O
of	O
passage	O
in	O
tissue	O
culture	O
,	O
a	O
process	O
first	O
described	O
in	O
196530	O
.	O

However	O
these	O
cells	O
can	O
be	O
stimulated	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
and	O
divide	O
further	O
by	O
transfecting	O
them	O
with	O
siRNAs	O
that	O
knock	O
down	O
components	O
of	O
the	O
p53	B-GP
signalling	O
pathway	O
,	O
including	O
p53	B-GP
itself	O
and	O
p2131	B-GP
.	O

Using	O
this	O
model	O
system	O
we	O
have	O
investigated	O
how	O
long	O
virus	B-OG
particles	O
can	O
remain	O
viable	O
once	O
exposed	O
to	O
senescent	O
cells	O
before	O
they	O
are	O
triggered	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
also	O
ascertained	O
where	O
virions	O
can	O
reside	O
long	O
-	O
term	O
in	O
the	O
cell	O
when	O
the	O
cell	O
is	O
outside	O
the	O
cell	O
cycle	O
and	O
before	O
induction	O
of	O
mitosis	O
.	O

To	O
our	O
surprise	O
,	O
we	O
find	O
that	O
under	O
these	O
conditions	O
virions	O
can	O
remain	O
infectious	O
for	O
several	O
weeks	O
,	O
not	O
in	O
internal	O
vesicular	O
compartments	O
but	O
instead	O
retained	O
on	O
the	O
cell	O
surface	O
in	O
a	O
location	O
accessible	O
to	O
neutralising	O
antibodies	B-GP
.	O

Materials	O
and	O
Methods	O

Cell	O
lines	O
and	O
transfections	O

Human	B-OG
diploid	O
foreskin	O
fibroblasts	O
(	O
BJ	O
,	O
ATCC	O
CRL	O
-	O
2522	O
)	O
were	O
a	O
generous	O
gift	O
from	O
Fabrizio	O
D	O
’	O
Adda	O
Di	O
Fagagna	O
’	O
s	O
laboratory	O
and	O
were	O
cultured	O
in	O
MEM	O
with	O
Glutamax	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
penicillin	O
-	O
streptomycin	O
(	O
1	O
%),	O
glutamine	O
(	O
2	O
mM	O
),	O
non	O
-	O
essential	O
amino	O
acids	O
(	O
10	O
mM	O
)	O
and	O
sodium	O
pyruvate	O
(	O
1	O
mM	O
).	O

In	O
order	O
to	O
be	O
able	O
to	O
observe	O
viral	O
persistence	O
in	O
non	O
-	O
dividing	O
cells	O
,	O
BJ	O
fibroblasts	O
were	O
serially	O
cultured	O
at	O
37	O
°	O
C	O
and	O
95	O
%	O
humidity	O
with	O
5	O
%	O
CO2	O
to	O
replicative	O
senescence	O
.	O

At	O
this	O
point	O
,	O
less	O
than	O
10	O
%	O
of	O
the	O
cells	O
incorporated	O
EdU	O
over	O
the	O
course	O
of	O
a	O
24	O
h	O
period	O
,	O
with	O
the	O
majority	O
of	O
cells	O
displaying	O
a	O
cell	O
cycle	O
arrest	O
.	O

Cells	O
were	O
either	O
subcultured	O
(	O
using	O
0	O
.	O
05	O
%	O
trypsin	B-GP
-	O
EDTA	O
)	O
or	O
submitted	O
to	O
a	O
medium	O
change	O
approximately	O
every	O
4	O
days	O
and	O
kept	O
at	O
a	O
maximum	O
confluence	O
of	O
approximately	O
90	O
%.	O

HeLa	O
cells	O
were	O
maintained	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
penicillin	O
-	O
streptomycin	O
(	O
1	O
%),	O
glutamine	O
(	O
2	O
mM	O
).	O

BJ	O
cells	O
were	O
transfected	O
following	O
a	O
reverse	O
transfection	O
protocol	O
using	O
Lipofectamine	O
RNAiMAX	O
(	O
Invitrogen	O
)	O
with	O
siRNAs	O
against	O
p53	B-GP
(	O
Sigma	O
)	O
or	O
non	O
-	O
targeting	O
siRNA	O
(	O
control	O
siRNA	O
,	O
Dharmacon	O
)	O
as	O
a	O
control	O
.	O

In	O
order	O
to	O
monitor	O
transfection	O
efficiencies	O
,	O
an	O
siRNA	O
targeting	O
the	O
ubiquitin	B-GP
complex	O
(	O
siUBC	O
,	O
Dharmacon	O
)	O
was	O
used	O
in	O
all	O
assays	O
,	O
which	O
is	O
cytotoxic	O
after	O
successful	O
transfection	O
,	O
and	O
verified	O
transfection	O
efficiencies	O
of	O
over	O
90	O
%.	O

Cell	O
cycle	O
analysis	O
with	O
flow	O
cytometry	O

4	O
×	O
105	O
senescent	O
or	O
replicating	O
BJ	O
fibroblasts	O
were	O
plated	O
on	O
6	O
cm	O
dishes	O
.	O

Senescent	O
cells	O
were	O
reverse	O
transfected	O
with	O
control	O
or	O
p53	B-GP
siRNA	O
to	O
a	O
final	O
concentration	O
of	O
50	O
nM	O
.	O

Cells	O
were	O
harvested	O
72	O
h	O
post	O
-	O
transfection	O
and	O
cell	O
cycle	O
analysis	O
was	O
performed	O
with	O
a	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
(	O
FACS	O
)	O
by	O
measuring	O
DNA	O
content	O
using	O
propidium	O
iodide	O
staining	O
as	O
described	O
previously32	O
.	O

EdU	O
incorporation	O
assay	O

1	O
.	O
5	O
×	O
103	O
senescent	O
BJ	O
cells	O
were	O
reverse	O
transfected	O
in	O
a	O
384	O
-	O
well	O
plate	O
with	O
control	O
siRNA	O
,	O
p53	B-GP
siRNA	O
and	O
UBC	B-GP
siRNA	O
as	O
a	O
control	O
for	O
cell	O
viability	O
.	O

After	O
48	O
h	O
10	O
µM	O
EdU	O
was	O
added	O
to	O
the	O
cells	O
and	O
after	O
24	O
h	O
the	O
cells	O
were	O
fixed	O
and	O
stained	O
with	O
Click	O
-	O
IT	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

Western	O
blot	O

1	O
.	O
3	O
×	O
105	O
senescent	O
BJ	O
cells	O
were	O
untreated	O
or	O
reverse	O
transfected	O
in	O
a	O
6	O
-	O
well	O
plate	O
with	O
control	O
siRNA	O
or	O
p53	B-GP
siRNA	O
and	O
harvested	O
in	O
RIPA	O
buffer	O
after	O
72	O
h	O
.	O

Equal	O
amounts	O
of	O
protein	O
were	O
separated	O
using	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

The	O
p53	B-GP
protein	O
was	O
detected	O
using	O
the	O
anti	O
-	O
p53	B-GP
(	O
DO	O
-	O
1	O
)	O
mouse	B-OG
monoclonal	O
antibody	B-GP
(	O
sc	O
-	O
126	O
,	O
Santa	O
Cruz	O
Biotechnology	O
),	O
and	O
the	O
loading	O
control	O
alpha	B-GP
-	I-GP
actinin	I-GP
was	O
detected	O
using	O
the	O
rabbit	B-OG
anti	O
-	O
alpha	B-GP
-	I-GP
actinin	I-GP
(	O
H	O
-	O
300	O
)	O
polyclonal	O
antibody	B-GP
(	O
sc	O
-	O
15335	O
,	O
Santa	O
Cruz	O
Biotechnology	O
).	O

Western	O
blots	O
were	O
developed	O
using	O
appropriate	O
secondary	O
antibodies	B-GP
conjugated	O
to	O
HRP	B-GP
followed	O
by	O
ECL	O
detection	O
.	O

PsVs	O
production	O

Different	O
HPV	B-OG
-	O
PsVs	O
containing	O
a	O
luciferase	B-GP
reporter	O
plasmid	O
were	O
generated	O
in	O
293TT	O
cells	O
as	O
described	O
previously33	O
.	O

Purity	O
and	O
capsid	B-GP
protein	I-GP
content	O
were	O
determined	O
by	O
SDS	O
-	O
PAGE	O
and	O
Coomassie	O
Brilliant	O
blue	O
staining	O
,	O
while	O
the	O
encapsidated	O
DNA	O
was	O
quantified	O
using	O
Real	O
-	O
Time	O
PCR	O
and	O
the	O
copy	O
number	O
was	O
calculated	O
using	O
a	O
standard	O
curve	O
of	O
reporter	O
plasmid	O
DNA	O
.	O

AF488	O
-	O
labelled	O
PsVs	O
were	O
prepared	O
using	O
the	O
Alexa	O
Fluor	O
488	O
Protein	O
labelling	O
kit	O
(	O
Molecular	O
Probes	O
).	O

Infectivity	O
assay	O

BJ	O
senescent	O
cells	O
were	O
seeded	O
in	O
96	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
4	O
×	O
103	O
cells	O
per	O
well	O
,	O
and	O
exposed	O
to	O
100	O
vge	O
/	O
cell	O
of	O
luciferase	B-GP
reporter	O
positive	O
PsVs	O
.	O

1	O
,	O
13	O
or	O
27	O
days	O
post	O
-	O
infection	B-DS
(	O
with	O
cells	O
subjected	O
to	O
several	O
medium	O
changes	O
),	O
cell	O
division	O
was	O
activated	O
by	O
transfection	O
with	O
p53	B-GP
siRNA	O
and	O
harvested	O
72	O
h	O
later	O
(	O
constituting	O
4	O
,	O
16	O
or	O
30	O
days	O
post	O
-	O
infection	B-DS
).	O

Infection	B-DS
was	O
monitored	O
by	O
luminometric	O
analysis	O
of	O
firefly	B-OG
luciferase	B-GP
activity	O
using	O
the	O
Luciferase	B-GP
Assay	O
System	O
(	O
Promega	O
).	O

For	O
each	O
assay	O
,	O
PsVs	O
infection	B-DS
in	O
the	O
presence	O
of	O
control	O
siRNA	O
was	O
normalized	O
to	O
100	O
%,	O
which	O
was	O
then	O
used	O
to	O
calculate	O
the	O
percentage	O
increase	O
following	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
p53	B-GP
siRNA	O
.	O

To	O
compare	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
infectivity	O
in	O
different	O
cell	O
lines	O
,	O
BJ	O
early	O
passage	O
cells	O
and	O
HeLa	O
cells	O
were	O
seeded	O
in	O
a	O
96	O
-	O
well	O
plate	O
at	O
a	O
density	O
of	O
2	O
.	O
5	O
×	O
103	O
cells	O
per	O
well	O
,	O
and	O
exposed	O
to	O
100	O
vge	O
/	O
cell	O
of	O
luciferase	B-GP
reporter	O
-	O
positive	O
PsVs	O
.	O

Two	O
days	O
post	O
-	O
infection	B-DS
cells	O
were	O
lysed	O
and	O
analysed	O
for	O
luminescence	O
as	O
an	O
indication	O
of	O
efficient	O
infection	B-DS
.	O

Throughout	O
,	O
equal	O
amounts	O
of	O
total	O
cell	O
protein	O
extract	O
were	O
used	O
in	O
the	O
luciferase	B-GP
measurements	O
.	O

Transferrin	B-GP
uptake	O

For	O
analysis	O
of	O
transferrin	B-GP
internalisation	O
,	O
senescent	O
cells	O
were	O
reverse	O
transfected	O
with	O
control	O
siRNA	O
and	O
p53	B-GP
siRNA	O
and	O
plated	O
on	O
0	O
.	O
01	O
%	O
poly	O
-	O
L	O
-	O
lysine	O
-	O
coated	O
LabTek	O
8	O
-	O
well	O
chamber	O
slides	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
at	O
a	O
density	O
of	O
1	O
.	O
4	O
×	O
104	O
cells	O
per	O
well	O
.	O

72	O
h	O
after	O
transfection	O
cells	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
serum	O
-	O
free	O
MEM	O
Glutamax	O
with	O
addition	O
of	O
50	O
µg	O
/	O
ml	O
AF647	O
labelled	O
transferrin	B-GP
(	O
Molecular	O
Probes	O
).	O

Following	O
incubation	O
,	O
cells	O
were	O
washed	O
several	O
times	O
with	O
PBS	O
and	O
fixed	O
in	O
3	O
.	O
7	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
15	O
min	O
for	O
fluorescence	O
microscopy	O
analysis	O
.	O

Cells	O
were	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
with	O
10	O
%	O
goat	B-OG
serum	O
and	O
later	O
EEA1	B-GP
detection	O
was	O
performed	O
using	O
rabbit	B-OG
anti	O
-	O
EEA1	B-GP
(	O
C45B10	O
,	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
secondary	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
AF546	O
-	O
conjugated	O
antibody	B-GP
(	O
Molecular	O
Probes	O
).	O

Slides	O
were	O
visualised	O
using	O
a	O
Zeiss	O
Axiovert	O
100	O
M	O
microscope	O
attached	O
to	O
an	O
LSM	O
510	O
confocal	O
unit	O
.	O

Transferrin	B-GP
uptake	O
was	O
analysed	O
using	O
ImageJ	O
.	O

15	O
fields	O
acquired	O
with	O
a	O
confocal	O
microscope	O
were	O
analysed	O
per	O
condition	O
,	O
with	O
over	O
130	O
cells	O
in	O
total	O
analysed	O
for	O
both	O
control	O
and	O
treated	O
samples	O
.	O

The	O
mean	O
intensity	O
of	O
the	O
transferrin	B-GP
staining	O
was	O
measured	O
for	O
each	O
individual	O
cell	O
,	O
disregarding	O
the	O
cell	O
area	O
.	O

A	O
second	O
analysis	O
was	O
performed	O
whereby	O
the	O
integrated	O
intensity	O
(	O
the	O
product	O
of	O
mean	O
intensity	O
and	O
cell	O
area	O
)	O
was	O
used	O
to	O
represent	O
the	O
total	O
transferrin	B-GP
content	O
of	O
each	O
cell	O
.	O

Immunofluorescence	O

BJ	O
senescent	O
cells	O
were	O
reverse	O
transfected	O
with	O
control	O
siRNA	O
and	O
p53	B-GP
siRNA	O
and	O
seeded	O
on	O
LabTek	O
8	O
-	O
well	O
chambers	O
slides	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
at	O
a	O
density	O
of	O
1	O
.	O
4	O
×	O
104	O
cells	O
per	O
well	O
.	O

One	O
day	O
after	O
,	O
the	O
cells	O
were	O
exposed	O
to	O
500	O
vge	O
/	O
cell	O
of	O
AF488	O
-	O
labelled	O
PsVs	O
.	O

48	O
h	O
after	O
infection	B-DS
and	O
72	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
fixed	O
in	O
3	O
.	O
7	O
%	O
paraformaldehyde	O
for	O
15	O
min	O
,	O
incubated	O
for	O
1	O
h	O
with	O
10	O
%	O
goat	B-OG
serum	O
and	O
then	O
stained	O
using	O
antibodies	B-GP
for	O
early	O
endosomes	O
(	O
rabbit	B-OG
anti	O
-	O
EEA1	B-GP
,	O
C45B10	O
,	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
lysosomal	O
markers	O
(	O
mouse	B-OG
anti	O
-	O
LAMP1	B-GP
,	O
D4O1S	O
,	O
Cell	O
Signaling	O
Technology	O
).	O

Donkey	B-OG
anti	O
-	O
rabbit	B-OG
594	O
and	O
goat	B-OG
anti	O
-	O
mouse	B-OG
rhodamine	O
were	O
used	O
as	O
secondary	O
antibodies	B-GP
(	O
Molecular	O
Probes	O
).	O

Slides	O
were	O
visualised	O
using	O
a	O
Zeiss	O
Axiovert	O
100	O
M	O
microscope	O
attached	O
to	O
an	O
LSM	O
510	O
confocal	O
unit	O
.	O

Neutralisation	O
assay	O

Neutralisation	O
assays	O
were	O
performed	O
using	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
(	O
H16	O
.	O
V5	O
),	O
which	O
was	O
kindly	O
provided	O
by	O
Neil	O
Christensen34	O
.	O

In	O
infectivity	O
assays	O
neutralising	O
antibody	B-GP
was	O
added	O
to	O
the	O
medium	O
(	O
dilution	O
of	O
1	O
:	O
1000	O
)	O
24	O
h	O
prior	O
to	O
adding	O
siRNA	O
,	O
and	O
infectivity	O
was	O
measured	O
at	O
16	O
days	O
post	O
-	O
infection	B-DS
as	O
described	O
above	O
.	O

In	O
immunofluorescence	O
assays	O
cells	O
were	O
transfected	O
and	O
1	O
day	O
later	O
cells	O
were	O
infected	O
,	O
and	O
2	O
days	O
post	O
-	O
transfection	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
was	O
added	O
to	O
the	O
medium	O
at	O
a	O
dilution	O
of	O
1	O
:	O
200	O
.	O

Cells	O
were	O
fixed	O
3	O
days	O
post	O
-	O
transfection	O
and	O
neutralising	O
antibody	B-GP
was	O
visualised	O
using	O
secondary	O
goat	B-OG
anti	O
-	O
mouse	B-OG
rhodamine	O
antibody	B-GP
(	O
Molecular	O
Probes	O
).	O

Statistics	O

All	O
experiments	O
were	O
performed	O
at	O
least	O
in	O
triplicate	O
,	O
and	O
data	O
are	O
shown	O
as	O
mean	O
and	O
standard	O
deviation	O
.	O

Statistical	O
significance	O
was	O
calculated	O
using	O
the	O
GraphPad	O
prism	O
6	O
software	O
.	O

To	O
compare	O
two	O
groups	O
the	O
Student	O
’	O
s	O
t	O
-	O
test	O
was	O
performed	O
,	O
to	O
compare	O
several	O
samples	O
a	O
1	O
-	O
way	O
ANOVA	O
calculation	O
was	O
followed	O
by	O
Dunnett	O
’	O
s	O
multiple	O
comparison	O
test	O
.	O

A	O
p	O
-	O
value	O
below	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
and	O
throughout	O
the	O
p	O
-	O
values	O
have	O
been	O
defined	O
as	O
follows	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
,	O
****	O
p	O
<	O
0	O
.	O
0001	O
,	O
while	O
“	O
ns	O
”	O
represents	O
a	O
non	O
-	O
significant	O
p	O
-	O
value	O
above	O
0	O
.	O
05	O
.	O

Results	O

Previous	O
studies	O
have	O
shown	O
that	O
completion	O
of	O
mitosis	O
is	O
an	O
absolute	O
requirement	O
for	O
allowing	O
completion	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
infectious	O
entry24	O
,	O
25	O
.	O

However	O
we	O
have	O
been	O
interested	O
in	O
understanding	O
where	O
incoming	O
virions	O
reside	O
until	O
the	O
onset	O
of	O
mitosis	O
and	O
for	O
how	O
long	O
such	O
virions	O
can	O
remain	O
viable	O
.	O

In	O
order	O
to	O
address	O
these	O
questions	O
we	O
made	O
use	O
of	O
a	O
well	O
-	O
established	O
model	O
of	O
cellular	O
senescence	O
.	O

In	O
the	O
BJ	O
cell	O
model	O
,	O
early	O
passage	O
cells	O
grow	O
rapidly	O
,	O
but	O
following	O
extensive	O
periods	O
of	O
passage	O
they	O
enter	O
senescence	O
.	O

This	O
is	O
indeed	O
confirmed	O
in	O
Fig	O
.	O
1a	O
,	O
where	O
it	O
can	O
be	O
seen	O
that	O
late	O
passage	O
cells	O
show	O
very	O
low	O
levels	O
of	O
DNA	O
replication	O
.	O

However	O
,	O
transfection	O
of	O
a	O
p53	B-GP
siRNA	O
,	O
the	O
efficacy	O
of	O
which	O
was	O
verified	O
by	O
Western	O
blotting	O
in	O
Fig	O
.	O
1b	O
,	O
efficiently	O
reverses	O
the	O
senescent	O
phenotype	O
,	O
and	O
as	O
can	O
be	O
seen	O
from	O
the	O
EdU	O
incorporation	O
assay	O
in	O
Fig	O
.	O
1c	O
and	O
d	O
these	O
cells	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
and	O
activate	O
DNA	O
replication	O
.	O
Figure	O
1p53	O
siRNA	O
induces	O
senescent	O
BJ	O
cells	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
and	O
re	O
-	O
commence	O
proliferation	O
.	O

(	O
a	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
BJ	O
fibroblast	O
cell	O
cycle	O
.	O

Early	O
passage	O
untreated	O
BJ	O
fibroblasts	O
and	O
late	O
passage	O
(	O
senescent	O
)	O
BJ	O
fibroblasts	O
(	O
untreated	O
,	O
or	O
transfected	O
with	O
control	O
siRNA	O
or	O
p53	B-GP
siRNA	O
)	O
were	O
harvested	O
after	O
72	O
h	O
and	O
the	O
cell	O
cycle	O
was	O
analysed	O
using	O
propidium	O
iodide	O
incorporation	O
.	O

Note	O
that	O
senescent	O
cells	O
are	O
arrested	O
in	O
G0	O
and	O
appear	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
following	O
transfection	O
with	O
si	O
-	O
p53	B-GP
.	O

(	O
b	O
)	O
Western	O
blot	O
showing	O
p53	B-GP
expression	O
in	O
senescent	O
BJ	O
cells	O
.	O

Late	O
passage	O
(	O
senescent	O
)	O
BJ	O
fibroblasts	O
(	O
untreated	O
,	O
or	O
transfected	O
with	O
control	O
siRNA	O
or	O
p53	B-GP
siRNA	O
)	O
were	O
harvested	O
after	O
72	O
h	O
and	O
protein	O
analysis	O
was	O
performed	O
.	O

Alpha	B-GP
-	I-GP
actinin	I-GP
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Note	O
that	O
the	O
levels	O
of	O
p53	B-GP
in	O
senescent	O
fibroblasts	O
are	O
efficiently	O
reduced	O
by	O
the	O
siRNA	O
transfection	O
.	O

(	O
c	O
)	O
Cell	O
proliferation	O
analysis	O
using	O
an	O
EdU	O
incorporation	O
assay	O
.	O

Early	O
and	O
late	O
passage	O
(	O
senescent	O
)	O
fibroblasts	O
were	O
plated	O
(	O
untreated	O
or	O
reverse	O
transfected	O
with	O
control	O
siRNA	O
,	O
p53	B-GP
siRNA	O
or	O
siRNA	O
targeting	O
Ubiquitin	B-GP
C	I-GP
(	O
si	O
-	O
UBC	B-GP
)).	O

EdU	O
was	O
added	O
to	O
cells	O
48	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
labeled	O
for	O
24	O
h	O
and	O
then	O
fixed	O
.	O

The	O
incorporated	O
EdU	O
was	O
stained	O
with	O
Click	O
-	O
IT	O
(	O
green	O
),	O
with	O
cell	O
nuclei	O
counter	O
-	O
stained	O
with	O
Hoechst	O
33342	O
(	O
blue	O
).	O

(	O
d	O
)	O
Quantification	O
of	O
EdU	O
incorporation	O
.	O

Plates	O
were	O
acquired	O
using	O
the	O
Image	O
Xpress	O
micro	O
microscope	O
(	O
Molecular	O
Devices	O
)	O
and	O
analysed	O
using	O
MetaXpress	O
version	O
5	O
.	O
3	O
.	O
0	O
.	O
5	O
to	O
determine	O
percentage	O
of	O
EdU	O
incorporation	O
.	O

The	O
results	O
are	O
expressed	O
as	O
the	O
mean	O
of	O
three	O
independent	O
experiments	O
,	O
and	O
the	O
standard	O
deviations	O
are	O
shown	O
.	O

Note	O
that	O
cells	O
treated	O
with	O
p53	B-GP
siRNA	O
(	O
si	O
-	O
p53	B-GP
)	O
have	O
a	O
higher	O
proliferative	O
ability	O
than	O
cells	O
transfected	O
with	O
control	O
siRNA	O
.	O

Using	O
this	O
model	O
system	O
,	O
we	O
first	O
compared	O
the	O
ability	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
carrying	O
a	O
luciferase	B-GP
reporter	O
construct	O
to	O
infect	O
early	O
passage	O
BJ	O
fibroblasts	O
cells	O
and	O
cervical	B-DS
tumour	I-DS
-	O
derived	O
HeLa	O
cells	O
.	O

The	O
results	O
in	O
Fig	O
.	O
2a	O
show	O
that	O
the	O
BJ	O
fibroblasts	O
are	O
susceptible	O
to	O
infection	B-DS
with	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
,	O
although	O
somewhat	O
less	O
so	O
than	O
HeLa	O
cells	O
.	O

Having	O
found	O
that	O
BJ	O
fibroblasts	O
can	O
be	O
used	O
in	O
such	O
infection	B-DS
assays	O
,	O
we	O
next	O
compared	O
the	O
ability	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
carrying	O
a	O
luciferase	B-GP
reporter	O
gene	O
to	O
infect	O
early	O
and	O
late	O
passage	O
BJ	O
cells	O
.	O

As	O
can	O
be	O
seen	O
from	O
Fig	O
.	O
2b	O
,	O
early	O
passage	O
BJ	O
cells	O
are	O
efficiently	O
transduced	O
using	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
but	O
the	O
late	O
passage	O
senescent	O
cells	O
are	O
not	O
,	O
which	O
is	O
consistent	O
with	O
their	O
not	O
undergoing	O
cell	O
division	O
.	O

These	O
assays	O
were	O
then	O
repeated	O
in	O
the	O
presence	O
of	O
p53	B-GP
siRNA	O
,	O
and	O
as	O
can	O
be	O
seen	O
from	O
Fig	O
.	O
2c	O
,	O
this	O
renders	O
the	O
late	O
passage	O
cells	O
susceptible	O
to	O
HPV	B-DS
-	I-DS
16	I-DS
infection	I-DS
and	O
promotes	O
transduction	O
of	O
the	O
reporter	O
construct	O
,	O
consistent	O
with	O
reactivation	O
of	O
cell	O
division	O
,	O
allowing	O
the	O
incoming	O
viruses	B-OG
to	O
gain	O
access	O
to	O
the	O
nucleus	O
during	O
mitosis	O
.	O
Figure	O
2HPV	O
-	O
16	O
PsV	O
infection	B-DS
of	O
senescent	O
cells	O
is	O
restored	O
following	O
transfection	O
of	O
p53	B-GP
siRNA	O
.	O

(	O
a	O
)	O
Infectivity	O
assay	O
in	O
early	O
passage	O
BJ	O
and	O
HeLa	O
cells	O
.	O

Early	O
passage	O
untreated	O
BJ	O
fibroblasts	O
and	O
Hela	O
cells	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
.	O

Two	O
days	O
post	O
-	O
infection	B-DS
cells	O
were	O
lysed	O
and	O
analysed	O
for	O
luminescence	O
as	O
an	O
indication	O
of	O
efficient	O
infection	B-DS
.	O

The	O
results	O
are	O
expressed	O
as	O
the	O
means	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
and	O
the	O
standard	O
deviations	O
are	O
shown	O
.	O

(	O
b	O
)	O
Infectivity	O
assay	O
in	O
untreated	O
early	O
and	O
late	O
passage	O
BJ	O
cells	O
.	O

Early	O
passage	O
and	O
late	O
passage	O
(	O
senescent	O
)	O
untreated	O
BJ	O
cells	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
carrying	O
a	O
luciferase	B-GP
reporter	O
plasmid	O
.	O

Four	O
days	O
post	O
infection	B-DS
cells	O
were	O
lysed	O
and	O
analysed	O
for	O
luminescence	O
as	O
an	O
indication	O
of	O
efficient	O
infection	B-DS
.	O

The	O
results	O
are	O
expressed	O
as	O
the	O
means	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
and	O
the	O
standard	O
deviations	O
are	O
shown	O
.	O

Note	O
that	O
only	O
early	O
passage	O
untreated	O
BJ	O
cells	O
are	O
efficiently	O
transduced	O
using	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
,	O
while	O
untreated	O
late	O
passage	O
(	O
senescent	O
)	O
cells	O
are	O
not	O
.	O

(	O
c	O
)	O
Infectivity	O
assay	O
in	O
transfected	O
late	O
passage	O
BJ	O
cells	O
.	O

Senescent	O
BJ	O
fibroblasts	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
carrying	O
a	O
luciferase	B-GP
reporter	O
plasmid	O
and	O
24	O
h	O
later	O
transfected	O
with	O
control	O
siRNA	O
,	O
or	O
p53	B-GP
siRNA	O
.	O

Four	O
days	O
post	O
-	O
infection	B-DS
cells	O
were	O
lysed	O
and	O
analysed	O
for	O
luminescence	O
as	O
an	O
indication	O
of	O
efficient	O
infection	B-DS
.	O

The	O
results	O
are	O
expressed	O
as	O
the	O
mean	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
and	O
the	O
standard	O
deviations	O
are	O
shown	O
.	O

Note	O
that	O
late	O
passage	O
(	O
senescent	O
)	O
cells	O
are	O
only	O
efficiently	O
transduced	O
if	O
stimulated	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
through	O
p53	B-GP
siRNA	O
transfection	O
.	O

We	O
were	O
next	O
interested	O
in	O
investigating	O
how	O
long	O
the	O
virus	B-OG
can	O
survive	O
post	O
-	O
infection	B-DS
before	O
transfection	O
of	O
the	O
p53	B-GP
siRNA	O
.	O

To	O
do	O
this	O
,	O
late	O
passage	O
BJ	O
cells	O
were	O
exposed	O
to	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
,	O
and	O
after	O
24	O
h	O
the	O
cells	O
were	O
washed	O
and	O
medium	O
replaced	O
.	O

The	O
cells	O
were	O
then	O
cultured	O
for	O
13	O
days	O
and	O
27	O
days	O
,	O
after	O
which	O
they	O
were	O
transfected	O
with	O
the	O
p53	B-GP
siRNA	O
to	O
promote	O
cell	O
cycle	O
re	O
-	O
entry	O
.	O

HPV	B-OG
-	I-OG
16	I-OG
infectious	O
entry	O
was	O
then	O
measured	O
48	O
h	O
later	O
by	O
extracting	O
the	O
cells	O
and	O
measuring	O
luciferase	B-GP
activity	O
.	O

It	O
can	O
be	O
seen	O
from	O
Fig	O
.	O
3a	O
that	O
transfection	O
of	O
p53	B-GP
siRNA	O
into	O
senescent	O
cells	O
can	O
stimulate	O
transduction	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
16	O
days	O
after	O
exposure	O
to	O
the	O
virus	B-OG
.	O

However	O
,	O
if	O
the	O
cells	O
are	O
exposed	O
27	O
days	O
prior	O
to	O
transfection	O
of	O
the	O
p53	B-GP
siRNA	O
,	O
then	O
no	O
PsV	O
transduction	O
occurs	O
(	O
Fig	O
.	O
3b	O
).	O

This	O
indicates	O
that	O
wherever	O
the	O
incoming	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
reside	O
for	O
these	O
extended	O
periods	O
of	O
time	O
in	O
the	O
senescent	O
cells	O
,	O
they	O
can	O
remain	O
viable	O
and	O
capable	O
of	O
transducing	O
the	O
reporter	O
construct	O
upon	O
stimulation	O
of	O
cell	O
cycle	O
re	O
-	O
entry	O
for	O
at	O
least	O
2	O
weeks	O
,	O
but	O
most	O
likely	O
for	O
no	O
longer	O
than	O
4	O
weeks	O
.	O

This	O
suggests	O
that	O
in	O
a	O
normal	O
virus	B-DS
infection	I-DS
cells	O
need	O
not	O
be	O
immediately	O
proliferating	O
to	O
still	O
be	O
susceptible	O
to	O
virus	B-DS
infection	I-DS
,	O
and	O
that	O
quite	O
extended	O
periods	O
of	O
time	O
might	O
pass	O
before	O
proliferation	O
and	O
mitosis	O
commences	O
.	O
Figure	O
3HPV	O
-	O
16	O
PsVs	O
are	O
susceptible	O
to	O
antibody	B-GP
neutralization	O
for	O
2	O
weeks	O
on	O
senescent	O
cells	O
.	O

(	O
a	O
)	O
Infectivity	O
assay	O
at	O
16	O
days	O
post	O
-	O
infection	B-DS
.	O

Senescent	O
BJ	O
cells	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
containing	O
the	O
luciferase	B-GP
reporter	O
gene	O
.	O

After	O
13	O
days	O
,	O
cell	O
division	O
was	O
activated	O
by	O
transfection	O
with	O
p53	B-GP
siRNA	O
.	O

Cells	O
were	O
harvested	O
72	O
h	O
after	O
transfection	O
and	O
luciferase	B-GP
activity	O
was	O
measured	O
to	O
assess	O
the	O
levels	O
of	O
infection	B-DS
.	O

Additionally	O
,	O
the	O
day	O
before	O
adding	O
the	O
siRNA	O
the	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
H16	O
.	O
V5	O
neutralising	O
antibody	B-GP
(	O
1	O
:	O
200	O
).	O

The	O
results	O
are	O
expressed	O
as	O
the	O
means	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
and	O
the	O
standard	O
deviations	O
are	O
shown	O
.	O

(	O
b	O
)	O
Infectivity	O
assay	O
at	O
30	O
days	O
post	O
-	O
infection	B-DS
.	O

Senescent	O
BJ	O
cells	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
containing	O
the	O
luciferase	B-GP
reporter	O
gene	O
.	O

After	O
27	O
days	O
cell	O
division	O
was	O
activated	O
by	O
transfection	O
with	O
p53	B-GP
siRNA	O
.	O

Cells	O
were	O
harvested	O
72	O
h	O
after	O
transfection	O
and	O
luciferase	B-GP
activity	O
was	O
measured	O
to	O
assess	O
the	O
levels	O
of	O
infection	B-DS
.	O

Note	O
that	O
the	O
virus	B-OG
can	O
survive	O
on	O
the	O
cell	O
for	O
2	O
weeks	O
,	O
but	O
not	O
30	O
days	O
,	O
waiting	O
for	O
the	O
initiation	O
of	O
mitosis	O
to	O
allow	O
its	O
entry	O
into	O
the	O
nucleus	O
.	O

The	O
neutralising	O
antibody	B-GP
can	O
block	O
this	O
infection	B-DS
,	O
showing	O
that	O
the	O
virus	B-OG
is	O
localised	O
in	O
a	O
position	O
that	O
is	O
accessible	O
to	O
the	O
neutralising	O
antibody	B-GP
.	O

In	O
order	O
to	O
determine	O
where	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
might	O
reside	O
for	O
such	O
extended	O
periods	O
of	O
time	O
we	O
first	O
analysed	O
whether	O
the	O
virus	B-OG
was	O
susceptible	O
to	O
antibody	B-GP
-	O
induced	O
neutralisation	O
.	O

To	O
do	O
this	O
,	O
late	O
passage	O
cells	O
were	O
exposed	O
to	O
PsVs	O
as	O
before	O
,	O
and	O
left	O
for	O
a	O
total	O
of	O
16	O
days	O
.	O

The	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
(	O
H16	O
.	O
V5	O
)	O
was	O
added	O
to	O
the	O
cells	O
at	O
12	O
days	O
post	O
-	O
infection	B-DS
,	O
and	O
at	O
13	O
days	O
post	O
-	O
infection	B-DS
cells	O
were	O
transfected	O
with	O
the	O
p53	B-GP
siRNA	O
.	O

As	O
can	O
also	O
be	O
seen	O
from	O
Fig	O
.	O
3	O
,	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
are	O
readily	O
neutralised	O
by	O
addition	O
of	O
the	O
anti	O
-	O
L1	B-GP
antibody	B-GP
,	O
even	O
after	O
exposing	O
the	O
cells	O
to	O
virus	B-OG
12	O
days	O
earlier	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
virus	B-OG
is	O
most	O
likely	O
residing	O
on	O
,	O
or	O
very	O
close	O
to	O
the	O
cell	O
surface	O
,	O
in	O
a	O
compartment	O
that	O
can	O
be	O
accessed	O
by	O
the	O
anti	O
-	O
L1	B-GP
antibody	B-GP
.	O

We	O
were	O
then	O
interested	O
in	O
investigating	O
whether	O
a	O
panel	O
of	O
other	O
HPV	B-OG
types	O
could	O
similarly	O
infect	O
senescent	O
cells	O
when	O
they	O
are	O
stimulated	O
back	O
into	O
the	O
cell	O
cycle	O
following	O
transfection	O
of	O
a	O
p53	B-GP
siRNA	O
.	O

To	O
do	O
this	O
,	O
late	O
passage	O
BJ	O
cells	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
2	I-OG
,	O
HPV	B-OG
-	I-OG
5	I-OG
,	O
HPV	B-OG
-	I-OG
16	I-OG
,	O
HPV	B-OG
-	I-OG
18	I-OG
and	O
HPV	B-OG
-	I-OG
31	I-OG
PsVs	O
in	O
the	O
presence	O
or	O
absence	O
of	O
p53	B-GP
siRNA	O
.	O

After	O
72	O
h	O
the	O
cells	O
were	O
harvested	O
and	O
luciferase	B-GP
activity	O
measured	O
.	O

The	O
results	O
in	O
Fig	O
.	O
4	O
demonstrate	O
a	O
similar	O
stimulation	O
of	O
luciferase	B-GP
transduction	O
with	O
all	O
HPV	B-OG
types	O
tested	O
following	O
transfection	O
of	O
p53	B-GP
siRNA	O
,	O
indicating	O
similar	O
requirements	O
for	O
infectious	O
entry	O
amongst	O
these	O
different	O
HPV	B-OG
types	O
.	O
Figure	O
4Comparison	O
of	O
the	O
transduction	O
efficiencies	O
of	O
different	O
HPV	B-OG
types	O
in	O
siRNA	O
p53	B-GP
transfected	O
senescent	O
BJ	O
fibroblasts	O
.	O

Senescent	O
BJ	O
fibroblasts	O
were	O
infected	O
with	O
HPV	B-OG
-	I-OG
2	I-OG
,	O
HPV	B-OG
-	I-OG
5	I-OG
,	O
HPV	B-OG
-	I-OG
16	I-OG
,	O
HPV	B-OG
-	I-OG
18	I-OG
and	O
HPV	B-OG
-	I-OG
31	I-OG
PsVs	O
carrying	O
a	O
luciferase	B-GP
reporter	O
plasmid	O
and	O
24	O
h	O
later	O
transfected	O
with	O
control	O
siRNA	O
,	O
or	O
p53	B-GP
siRNA	O
.	O

Four	O
days	O
post	O
-	O
infection	B-DS
the	O
cells	O
were	O
lysed	O
and	O
luciferase	B-GP
activity	O
measured	O
.	O

The	O
results	O
are	O
expressed	O
as	O
the	O
mean	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
and	O
the	O
standard	O
deviations	O
are	O
shown	O
.	O

Obviously	O
an	O
important	O
concern	O
from	O
these	O
analyses	O
was	O
whether	O
or	O
not	O
the	O
senescent	O
cells	O
were	O
still	O
undergoing	O
endocytosis	O
.	O

In	O
order	O
to	O
monitor	O
this	O
we	O
analysed	O
transferrin	B-GP
uptake	O
in	O
senescent	O
cells	O
and	O
in	O
cells	O
transfected	O
with	O
p53	B-GP
siRNA	O
.	O

At	O
72	O
h	O
post	O
-	O
transfection	O
cells	O
were	O
incubated	O
with	O
AF647	O
-	O
labelled	O
transferrin	B-GP
for	O
30	O
minutes	O
before	O
cell	O
fixation	O
,	O
and	O
then	O
stained	O
for	O
the	O
early	O
endosomal	O
marker	O
EEA1	B-GP
.	O

As	O
can	O
be	O
seen	O
from	O
Fig	O
.	O
5	O
,	O
there	O
is	O
no	O
major	O
change	O
in	O
endocytic	O
uptake	O
of	O
transferrin	B-GP
in	O
the	O
p53	B-GP
siRNA	O
-	O
transfected	O
senescent	O
cells	O
,	O
indicating	O
that	O
lack	O
of	O
virus	B-OG
uptake	O
is	O
not	O
due	O
to	O
the	O
simple	O
shutting	O
down	O
of	O
endocytic	O
transport	O
pathways	O
.	O

This	O
is	O
supported	O
by	O
the	O
quantifications	O
from	O
multiple	O
assays	O
when	O
looking	O
at	O
the	O
average	O
transferrin	B-GP
intensity	O
per	O
cell	O
,	O
but	O
also	O
when	O
integrating	O
transferrin	B-GP
intensity	O
,	O
where	O
the	O
average	O
intensity	O
of	O
transferrin	B-GP
is	O
multiplied	O
by	O
the	O
cell	O
area	O
.	O
Figure	O
5Transferrin	O
uptake	O
in	O
senescent	O
cells	O
is	O
not	O
improved	O
by	O
re	O
-	O
stimulating	O
cell	O
cycle	O
entry	O
.	O

Senescent	O
BJ	O
cells	O
were	O
transfected	O
with	O
control	O
siRNA	O
and	O
p53	B-GP
siRNA	O
.	O

72	O
h	O
post	O
-	O
transfection	O
cells	O
were	O
incubated	O
with	O
AF647	O
-	O
labelled	O
transferrin	B-GP
for	O
30	O
minutes	O
before	O
cell	O
fixation	O
.	O

Transferrin	B-GP
(	O
blue	O
)	O
co	O
-	O
localises	O
with	O
early	O
endosomes	O
EEA1	B-GP
(	O
red	O
)	O
30	O
minutes	O
after	O
its	O
uptake	O
.	O

Representative	O
images	O
are	O
shown	O
in	O
panel	O
(	O
a	O
)	O
and	O
quantification	O
of	O
transferrin	B-GP
uptake	O
is	O
shown	O
in	O
panel	O
(	O
b	O
),	O
calculated	O
as	O
average	O
intensity	O
and	O
integrated	O
intensity	O
(	O
representing	O
total	O
amount	O
).	O

Note	O
that	O
transferrin	B-GP
uptake	O
and	O
distribution	O
is	O
similar	O
in	O
senescent	O
(	O
control	O
siRNA	O
)	O
and	O
proliferating	O
cells	O
(	O
si	O
-	O
p53	B-GP
),	O
with	O
no	O
statistically	O
significant	O
differences	O
in	O
uptake	O
regardless	O
of	O
analysis	O
method	O
.	O

Having	O
found	O
that	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
remained	O
antibody	B-GP
-	O
neutralisable	O
for	O
an	O
extended	O
period	O
post	O
-	O
infection	B-DS
in	O
the	O
senescent	O
cells	O
,	O
we	O
then	O
proceeded	O
to	O
investigate	O
in	O
more	O
detail	O
where	O
such	O
virions	O
might	O
reside	O
prior	O
to	O
cell	O
cycle	O
re	O
-	O
entry	O
.	O

We	O
first	O
performed	O
a	O
series	O
of	O
analyses	O
using	O
Alexa	O
Fluor	O
-	O
labelled	O
(	O
AF488	O
)	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
,	O
where	O
cells	O
were	O
first	O
reverse	O
transfected	O
with	O
the	O
siRNAs	O
,	O
infected	O
after	O
24	O
h	O
and	O
fixed	O
48	O
h	O
post	O
-	O
infection	B-DS
.	O

Cells	O
were	O
then	O
stained	O
for	O
the	O
endosomal	O
marker	O
EEA1	B-GP
and	O
the	O
lysosomal	O
marker	O
LAMP1	B-GP
.	O

The	O
results	O
in	O
Fig	O
.	O
6	O
demonstrate	O
no	O
extensive	O
co	O
-	O
localisation	O
between	O
the	O
AF488	O
-	O
labelled	O
virus	B-OG
and	O
either	O
EEA1	B-GP
or	O
LAMP1	B-GP
in	O
the	O
senescent	O
cells	O
,	O
consistent	O
with	O
the	O
virus	B-OG
not	O
entering	O
these	O
cells	O
.	O

Indeed	O
,	O
in	O
many	O
cases	O
the	O
virus	B-OG
appears	O
to	O
accumulate	O
at	O
the	O
cell	O
periphery	O
.	O

In	O
contrast	O
,	O
in	O
cells	O
transfected	O
with	O
the	O
p53	B-GP
siRNA	O
there	O
is	O
clear	O
evidence	O
of	O
virus	B-OG
co	O
-	O
localisation	O
with	O
EEA1	B-GP
and	O
LAMP1	B-GP
,	O
demonstrating	O
that	O
stimulation	O
of	O
cell	O
cycle	O
re	O
-	O
entry	O
also	O
stimulates	O
endocytic	O
uptake	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
.	O
Figure	O
6HPV	O
-	O
16	O
PsVs	O
trafficking	O
to	O
early	O
and	O
late	O
endosomes	O
is	O
affected	O
in	O
senescent	O
cells	O
.	O

Senescent	O
BJ	O
cells	O
were	O
transfected	O
with	O
control	O
siRNA	O
and	O
p53	B-GP
siRNA	O
.	O

One	O
day	O
after	O
transfection	O
,	O
cells	O
were	O
exposed	O
to	O
Alexa	O
Fluor	O
488	O
-	O
labelled	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
(	O
green	O
)	O
for	O
48	O
h	O
then	O
fixed	O
and	O
stained	O
for	O
endogenous	O
EEA	B-GP
-	I-GP
1	I-GP
using	O
rabbit	B-OG
antibody	B-GP
against	O
EEA	B-GP
-	I-GP
1	I-GP
and	O
detected	O
using	O
Alexa	O
Fluor	O
594	O
-	O
conjugated	O
donkey	B-OG
anti	O
-	O
rabbit	B-OG
antibody	B-GP
(	O
red	O
)	O
(	O
a	O
)	O
and	O
for	O
endogenous	O
LAMP1	B-GP
using	O
mouse	B-OG
antibody	B-GP
against	O
LAMP1	B-GP
and	O
detected	O
using	O
rhodamine	O
red	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
antibody	B-GP
(	O
red	O
)	O
(	O
b	O
).	O

Shown	O
are	O
two	O
representative	O
merged	O
images	O
for	O
each	O
condition	O
.	O

Note	O
that	O
in	O
senescent	O
cells	O
(	O
control	O
)	O
the	O
virus	B-OG
is	O
mainly	O
localised	O
on	O
the	O
surface	O
of	O
the	O
cells	O
and	O
shows	O
very	O
little	O
co	O
-	O
localisation	O
with	O
early	O
endosomes	O
(	O
a	O
)	O
and	O
late	O
endosomes	O
(	O
b	O
)	O
in	O
comparison	O
with	O
proliferating	O
cells	O
(	O
si	O
-	O
p53	B-GP
).	O

The	O
above	O
results	O
indicate	O
that	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
most	O
probably	O
reside	O
on	O
the	O
surface	O
of	O
the	O
senescent	O
cells	O
,	O
and	O
are	O
only	O
endocytosed	O
once	O
the	O
cells	O
are	O
stimulated	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
following	O
the	O
transfection	O
of	O
the	O
p53	B-GP
siRNA	O
.	O

We	O
then	O
wanted	O
to	O
investigate	O
whether	O
we	O
could	O
visualise	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
(	O
H16	O
.	O
V5	O
)	O
co	O
-	O
localising	O
with	O
the	O
surface	O
-	O
bound	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
in	O
the	O
senescent	O
cells	O
.	O

To	O
do	O
this	O
,	O
the	O
cells	O
were	O
transfected	O
with	O
control	O
or	O
p53	B-GP
siRNA	O
and	O
after	O
24	O
h	O
infected	O
with	O
AF488	O
-	O
labelled	O
virus	B-OG
;	O
after	O
an	O
additional	O
24	O
h	O
the	O
medium	O
was	O
changed	O
and	O
non	O
-	O
fixed	O
,	O
non	O
-	O
permeabilised	O
cells	O
were	O
incubated	O
with	O
the	O
anti	O
-	O
L1	B-GP
antibody	B-GP
.	O

Finally	O
,	O
one	O
day	O
later	O
,	O
the	O
cells	O
were	O
washed	O
and	O
fixed	O
and	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
was	O
detected	O
by	O
staining	O
with	O
rhodamine	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
antibody	B-GP
.	O

As	O
can	O
be	O
seen	O
from	O
Fig	O
.	O
7a	O
,	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
binds	O
to	O
the	O
surface	O
of	O
uninfected	O
BJ	O
cells	O
,	O
and	O
this	O
pattern	O
does	O
not	O
change	O
significantly	O
following	O
transfection	O
of	O
the	O
p53	B-GP
siRNA	O
.	O

This	O
indicates	O
that	O
these	O
antibodies	B-GP
can	O
bind	O
to	O
the	O
surface	O
of	O
these	O
senescent	O
cells	O
probably	O
through	O
Fc	B-GP
receptors	I-GP
on	O
the	O
cell	O
surface	O
.	O

However	O
,	O
in	O
cells	O
that	O
have	O
been	O
infected	O
with	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
and	O
transfected	O
with	O
the	O
control	O
siRNA	O
(	O
Fig	O
.	O
7b	O
)	O
it	O
is	O
quite	O
clear	O
that	O
the	O
AF488	O
-	O
labelled	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
are	O
located	O
mostly	O
on	O
the	O
cell	O
surface	O
,	O
and	O
there	O
is	O
clear	O
co	O
-	O
localisation	O
in	O
many	O
cases	O
with	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
.	O

These	O
results	O
thus	O
confirm	O
that	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
in	O
the	O
non	O
-	O
dividing	O
cells	O
are	O
readily	O
accessible	O
to	O
the	O
neutralising	O
antibody	B-GP
owing	O
to	O
the	O
virus	B-OG
accumulating	O
at	O
a	O
surface	O
-	O
exposed	O
location	O
.	O

In	O
contrast	O
,	O
in	O
cells	O
transfected	O
with	O
the	O
p53	B-GP
siRNA	O
,	O
the	O
bulk	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
have	O
entered	O
the	O
cells	O
while	O
the	O
anti	O
-	O
L1	B-GP
antibody	B-GP
is	O
still	O
present	O
on	O
the	O
cell	O
surface	O
.	O

Under	O
these	O
conditions	O
there	O
is	O
very	O
little	O
co	O
-	O
localisation	O
between	O
the	O
AF488	O
-	O
labelled	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
and	O
the	O
anti	O
-	O
L1	B-GP
antibody	B-GP
.	O

These	O
results	O
demonstrate	O
that	O
in	O
non	O
-	O
dividing	O
senescent	O
cells	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
remain	O
bound	O
to	O
the	O
cell	O
surface	O
,	O
in	O
a	O
location	O
accessible	O
to	O
neutralising	O
antibodies	B-GP
.	O

However	O
,	O
following	O
stimulation	O
of	O
cell	O
cycle	O
re	O
-	O
entry	O
there	O
is	O
rapid	O
internalisation	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
which	O
are	O
then	O
no	O
longer	O
accessible	O
to	O
the	O
anti	O
-	O
L1	B-GP
antibody	B-GP
.	O
Figure	O
7HPV	O
-	O
16	O
PsVs	O
in	O
senescent	O
cells	O
are	O
accessible	O
to	O
neutralising	O
antibody	B-GP
.	O

(	O
a	O
)	O
Anti	O
-	O
L1	B-GP
(	O
H16	O
.	O
V5	O
)	O
neutralising	O
antibody	B-GP
binds	O
to	O
the	O
surface	O
of	O
senescent	O
and	O
proliferating	O
cells	O
.	O

Senescent	O
BJ	O
cells	O
were	O
transfected	O
with	O
control	O
siRNA	O
and	O
p53	B-GP
siRNA	O
.	O

48	O
h	O
after	O
transfection	O
cells	O
were	O
incubated	O
with	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
for	O
24	O
h	O
.	O

Then	O
cells	O
were	O
fixed	O
and	O
neutralising	O
antibody	B-GP
was	O
detected	O
with	O
goat	B-OG
anti	O
-	O
mouse	B-OG
rhodamine	O
antibody	B-GP
(	O
red	O
)	O
and	O
rabbit	B-OG
antibody	B-GP
against	O
EEA	B-GP
-	I-GP
1	I-GP
,	O
and	O
detected	O
using	O
Alexa	O
Fluor	O
647	O
-	O
conjugated	O
donkey	B-OG
anti	O
-	O
rabbit	B-OG
(	O
blue	O
).	O

Two	O
examples	O
are	O
shown	O
for	O
each	O
condition	O
.	O

(	O
b	O
)	O
In	O
infected	O
senescent	O
cells	O
the	O
H16	O
.	O
V5	O
neutralising	O
antibody	B-GP
co	O
-	O
localises	O
with	O
the	O
virus	B-OG
on	O
the	O
surface	O
of	O
cells	O
.	O

One	O
day	O
after	O
siRNA	O
transfection	O
,	O
AF488	O
-	O
labelled	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
(	O
green	O
)	O
were	O
added	O
to	O
the	O
cells	O
.	O

24	O
h	O
after	O
infection	B-DS
cells	O
were	O
incubated	O
overnight	O
with	O
neutralising	O
H16	O
.	O
V5	O
antibody	B-GP
,	O
fixed	O
and	O
stained	O
as	O
above	O
.	O

Note	O
that	O
in	O
senescent	O
cells	O
transfected	O
with	O
the	O
control	O
siRNA	O
,	O
H16	O
.	O
V5	O
neutralising	O
antibody	B-GP
co	O
-	O
localises	O
with	O
the	O
virus	B-OG
on	O
the	O
cell	O
surface	O
(	O
indicated	O
by	O
arrows	O
).	O

In	O
cells	O
that	O
were	O
transfected	O
with	O
the	O
p53	B-GP
siRNA	O
there	O
is	O
very	O
little	O
co	O
-	O
localisation	O
between	O
the	O
virus	B-OG
and	O
neutralising	O
antibody	B-GP
and	O
virus	B-OG
is	O
visible	O
within	O
the	O
cells	O
,	O
as	O
indicated	O
by	O
the	O
arrows	O
,	O
suggesting	O
that	O
virus	B-OG
entry	O
is	O
stimulated	O
post	O
–	O
transfection	O
of	O
the	O
p53	B-GP
siRNA	O
.	O

Discussion	O

HPV	B-OG
infectious	O
entry	O
involves	O
a	O
complex	O
series	O
of	O
steps	O
,	O
which	O
includes	O
interaction	O
with	O
extracellular	O
matrix	O
,	O
structural	O
remodelling	O
of	O
the	O
virion	O
,	O
and	O
receptor	O
attachment	O
,	O
followed	O
by	O
endocytosis	O
and	O
the	O
recruitment	O
of	O
different	O
components	O
of	O
the	O
cellular	O
transport	O
machinery	O
to	O
ensure	O
delivery	O
of	O
the	O
incoming	O
viral	O
genomes	O
to	O
the	O
trans	O
-	O
Golgi	O
network35	O
.	O

Upon	O
entry	O
into	O
mitosis	O
,	O
the	O
nuclear	O
envelope	O
is	O
lost	O
and	O
the	O
viral	O
L2	B-GP
/	O
DNA	O
complex	O
gains	O
access	O
to	O
the	O
nucleus	O
where	O
it	O
resides	O
in	O
PODs	O
and	O
where	O
initiation	O
of	O
viral	O
gene	O
expression	O
then	O
takes	O
place7	O
,	O
8	O
.	O

The	O
success	O
of	O
this	O
entry	O
process	O
is	O
thus	O
intimately	O
linked	O
to	O
the	O
onset	O
of	O
mitosis24	O
,	O
25	O
.	O

Some	O
major	O
questions	O
arise	O
from	O
those	O
studies	O
.	O

In	O
particular	O
,	O
how	O
long	O
can	O
the	O
incoming	O
HPVs	B-OG
remain	O
viable	O
within	O
the	O
infected	O
cell	O
prior	O
to	O
the	O
onset	O
of	O
mitosis	O
and	O
where	O
do	O
they	O
reside	O
during	O
this	O
period	O
?	O

Here	O
we	O
have	O
attempted	O
to	O
provide	O
some	O
insights	O
into	O
these	O
questions	O
.	O

Using	O
a	O
well	O
-	O
established	O
model	O
of	O
reversible	O
cell	O
senescence31	O
,	O
we	O
have	O
been	O
able	O
to	O
show	O
that	O
incoming	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
can	O
remain	O
viable	O
for	O
up	O
to	O
13	O
days	O
post	O
-	O
exposure	O
to	O
the	O
target	O
cells	O
,	O
and	O
can	O
efficiently	O
transduce	O
cells	O
after	O
such	O
a	O
period	O
of	O
time	O
if	O
the	O
cells	O
are	O
stimulated	O
to	O
re	O
-	O
enter	O
the	O
cell	O
cycle	O
.	O

To	O
our	O
surprise	O
however	O
,	O
we	O
find	O
that	O
these	O
viruses	B-OG
are	O
still	O
sensitive	O
to	O
neutralisation	O
by	O
an	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
,	O
indicating	O
that	O
the	O
virus	B-OG
is	O
located	O
on	O
or	O
near	O
the	O
cell	O
surface	O
during	O
the	O
whole	O
of	O
this	O
period	O
and	O
is	O
not	O
retained	O
in	O
an	O
intracellular	O
vesicular	O
compartment	O
.	O

These	O
results	O
obviously	O
have	O
major	O
implications	O
for	O
our	O
understanding	O
of	O
how	O
long	O
viruses	B-OG
can	O
remain	O
viable	O
without	O
the	O
target	O
cell	O
entering	O
mitosis	O
,	O
but	O
nonetheless	O
still	O
being	O
accessible	O
to	O
antibody	B-GP
neutralisation	O
.	O

Using	O
the	O
BJ	O
model	O
of	O
replicative	O
senescence	O
we	O
could	O
first	O
confirm	O
previous	O
studies	O
showing	O
that	O
these	O
cells	O
gradually	O
cease	O
to	O
proliferate	O
following	O
extended	O
periods	O
in	O
tissue	O
culture	O
.	O

However	O
,	O
cell	O
cycle	O
re	O
-	O
entry	O
can	O
be	O
efficiently	O
induced	O
in	O
these	O
senescent	O
cells	O
following	O
transfection	O
of	O
a	O
p53	B-GP
siRNA	O
.	O

Using	O
this	O
model	O
we	O
first	O
compared	O
the	O
ability	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
to	O
transduce	O
a	O
luciferase	B-GP
reporter	O
construct	O
into	O
early	O
passage	O
(	O
proliferating	O
)	O
and	O
late	O
passage	O
(	O
senescent	O
)	O
BJ	O
cells	O
.	O

Not	O
surprisingly	O
,	O
we	O
found	O
very	O
good	O
levels	O
of	O
transduction	O
in	O
the	O
early	O
passage	O
cells	O
,	O
confirming	O
that	O
many	O
different	O
cell	O
types	O
,	O
including	O
fibroblasts	O
,	O
are	O
susceptible	O
to	O
infection	B-DS
with	O
HPV	B-OG
PsVs36	O
,	O
37	O
.	O

In	O
addition	O
,	O
we	O
also	O
confirmed	O
earlier	O
studies	O
demonstrating	O
an	O
absolute	O
requirement	O
for	O
cell	O
proliferation	O
for	O
the	O
infectious	O
entry	O
to	O
be	O
successful	O
,	O
with	O
only	O
very	O
low	O
levels	O
of	O
reporter	O
gene	O
transduction	O
being	O
obtained	O
in	O
the	O
senescent	O
cell	O
population	O
.	O

However	O
,	O
the	O
efficacy	O
of	O
the	O
model	O
was	O
demonstrated	O
following	O
transfection	O
of	O
the	O
senescent	O
cells	O
with	O
a	O
p53	B-GP
siRNA	O
;	O
this	O
induced	O
cell	O
cycle	O
re	O
-	O
entry	O
and	O
rendered	O
the	O
cells	O
susceptible	O
to	O
infection	B-DS
with	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
.	O

Using	O
this	O
model	O
of	O
inducible	O
cell	O
cycle	O
re	O
-	O
entry	O
,	O
we	O
first	O
investigated	O
how	O
long	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
could	O
remain	O
infectious	O
after	O
being	O
exposed	O
to	O
the	O
cells	O
,	O
but	O
prior	O
to	O
the	O
cells	O
undergoing	O
mitosis	O
.	O

We	O
found	O
that	O
virions	O
were	O
remarkably	O
stable	O
in	O
these	O
assays	O
,	O
and	O
could	O
readily	O
attain	O
complete	O
infectious	O
entry	O
,	O
as	O
determined	O
by	O
luciferase	B-GP
transduction	O
,	O
for	O
up	O
to	O
16	O
days	O
post	O
-	O
infection	B-DS
.	O

However	O
,	O
by	O
30	O
days	O
,	O
no	O
sign	O
of	O
infectivity	O
remained	O
,	O
indicating	O
that	O
virions	O
can	O
remain	O
infectious	O
on	O
a	O
target	O
cell	O
for	O
2	O
weeks	O
before	O
the	O
cell	O
enters	O
the	O
cell	O
division	O
cycle	O
and	O
completes	O
mitosis	O
.	O

It	O
should	O
be	O
emphasised	O
that	O
the	O
ability	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
to	O
infect	O
these	O
cells	O
is	O
not	O
due	O
to	O
the	O
residual	O
presence	O
of	O
free	O
virus	B-OG
in	O
the	O
medium	O
,	O
as	O
we	O
were	O
never	O
able	O
to	O
obtain	O
infectious	O
virus	B-OG
from	O
the	O
tissue	O
culture	O
supernatants	O
;	O
rather	O
it	O
indicates	O
the	O
presence	O
of	O
virus	B-OG
either	O
strongly	O
bound	O
or	O
internalised	O
in	O
the	O
target	O
cells	O
(	O
data	O
not	O
shown	O
).	O

At	O
this	O
stage	O
we	O
do	O
not	O
know	O
the	O
fate	O
of	O
the	O
virus	B-OG
between	O
the	O
16	O
-	O
and	O
30	O
-	O
day	O
time	O
points	O
,	O
as	O
we	O
have	O
been	O
unable	O
to	O
recover	O
infectious	O
virus	B-OG
from	O
these	O
cells	O
.	O

Future	O
studies	O
will	O
be	O
required	O
to	O
investigate	O
this	O
aspect	O
further	O
.	O

Obviously	O
,	O
a	O
major	O
question	O
arising	O
from	O
this	O
analysis	O
was	O
;	O
where	O
within	O
the	O
cell	O
does	O
the	O
virus	B-OG
reside	O
whilst	O
the	O
cell	O
is	O
in	O
a	O
senescent	O
state	O
for	O
these	O
extended	O
periods	O
of	O
time	O
?	O

We	O
provide	O
strong	O
evidence	O
that	O
under	O
these	O
circumstances	O
,	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
do	O
not	O
actually	O
enter	O
an	O
internal	O
vesicular	O
compartment	O
,	O
but	O
remain	O
attached	O
to	O
the	O
cell	O
surface	O
.	O

Several	O
lines	O
of	O
evidence	O
support	O
this	O
conclusion	O
.	O

Firstly	O
in	O
all	O
assays	O
,	O
we	O
found	O
that	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
could	O
very	O
effectively	O
abolish	O
virus	B-DS
infection	I-DS
,	O
even	O
in	O
cultures	O
where	O
the	O
cells	O
had	O
been	O
exposed	O
to	O
virions	O
nearly	O
two	O
weeks	O
prior	O
to	O
neutralisation	O
.	O

Secondly	O
,	O
immunofluorescence	O
analyses	O
failed	O
to	O
show	O
any	O
co	O
-	O
localisation	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
with	O
either	O
endosomes	O
or	O
lysosomes	O
in	O
senescent	O
cells	O
,	O
and	O
such	O
co	O
-	O
localisation	O
was	O
only	O
observed	O
following	O
transfection	O
of	O
the	O
cells	O
with	O
p53	B-GP
siRNA	O
to	O
promote	O
cell	O
cycle	O
re	O
-	O
entry	O
.	O

Indeed	O
,	O
in	O
the	O
senescent	O
cells	O
there	O
was	O
consistent	O
indication	O
of	O
AF488	O
-	O
labelled	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
accumulating	O
on	O
the	O
cell	O
surface	O
.	O

In	O
agreement	O
with	O
this	O
,	O
we	O
found	O
that	O
when	O
non	O
-	O
fixed	O
non	O
-	O
permeabilised	O
cells	O
were	O
exposed	O
to	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
,	O
this	O
could	O
co	O
-	O
localise	O
with	O
cell	O
-	O
surface	O
-	O
bound	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
in	O
the	O
senescent	O
cells	O
.	O

However	O
when	O
the	O
same	O
assay	O
was	O
performed	O
on	O
cells	O
that	O
had	O
been	O
stimulated	O
to	O
enter	O
the	O
cell	O
cycle	O
,	O
following	O
transfection	O
of	O
the	O
p53	B-GP
siRNA	O
,	O
there	O
was	O
strongly	O
reduced	O
co	O
-	O
localisation	O
of	O
the	O
AF488	O
-	O
labelled	O
PsVs	O
and	O
the	O
anti	O
-	O
L1	B-GP
neutralising	O
antibody	B-GP
.	O

An	O
important	O
point	O
arising	O
from	O
these	O
studies	O
was	O
whether	O
the	O
senescent	O
cells	O
were	O
simply	O
defective	O
in	O
endocytic	O
uptake	O
.	O

However	O
in	O
an	O
extensive	O
series	O
of	O
assays	O
looking	O
at	O
transferrin	B-GP
uptake	O
,	O
we	O
observed	O
no	O
major	O
differences	O
between	O
the	O
senescent	O
cells	O
and	O
those	O
that	O
were	O
stimulated	O
back	O
into	O
cell	O
cycle	O
following	O
transfection	O
of	O
p53	B-GP
siRNA	O
.	O

Obviously	O
,	O
these	O
studies	O
have	O
the	O
caveat	O
of	O
being	O
performed	O
in	O
fibroblasts	O
and	O
not	O
in	O
basal	O
keratinocytes	O
,	O
the	O
natural	O
target	O
cell	O
for	O
these	O
viruses	B-OG
.	O

Indeed	O
,	O
when	O
comparing	O
infectivity	O
of	O
early	O
passage	O
BJ	O
fibroblasts	O
with	O
HeLa	O
cells	O
we	O
do	O
indeed	O
see	O
significantly	O
lower	O
levels	O
of	O
infectivity	O
in	O
the	O
fibroblasts	O
.	O

Unfortunately	O
we	O
have	O
not	O
been	O
able	O
to	O
identify	O
conditions	O
whereby	O
keratinocytes	O
can	O
be	O
maintained	O
in	O
a	O
growth	O
-	O
arrested	O
state	O
for	O
several	O
weeks	O
,	O
making	O
it	O
impossible	O
to	O
perform	O
similar	O
studies	O
in	O
that	O
cell	O
setting	O
.	O

However	O
,	O
these	O
studies	O
nonetheless	O
demonstrate	O
an	O
intriguing	O
capacity	O
of	O
the	O
virus	B-OG
to	O
remain	O
viable	O
on	O
the	O
surface	O
of	O
senescent	O
cells	O
for	O
extended	O
periods	O
of	O
time	O
,	O
and	O
it	O
is	O
reasonable	O
to	O
speculate	O
that	O
this	O
is	O
also	O
relevant	O
for	O
HPV	B-OG
PsV	O
interactions	O
with	O
other	O
cell	O
types	O
.	O

Taken	O
together	O
,	O
these	O
results	O
have	O
a	O
number	O
of	O
important	O
implications	O
.	O

They	O
once	O
again	O
highlight	O
the	O
importance	O
of	O
mitosis	O
for	O
completion	O
of	O
virus	B-DS
infection	I-DS
,	O
but	O
they	O
also	O
make	O
a	O
further	O
compelling	O
case	O
that	O
active	O
growth	O
-	O
promoting	O
signalling	O
is	O
required	O
for	O
virus	B-OG
uptake	O
to	O
actually	O
take	O
place	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
EGFR	B-GP
signalling	O
was	O
most	O
likely	O
required	O
for	O
virion	O
uptake	O
,	O
and	O
certainly	O
blocking	O
EGFR	B-GP
with	O
an	O
inhibitory	O
antibody	B-GP
blocks	O
virus	B-OG
entry	O
,	O
suggesting	O
its	O
possible	O
use	O
as	O
an	O
entry	O
receptor28	O
,	O
29	O
.	O

Our	O
studies	O
do	O
not	O
exclude	O
this	O
possibility	O
,	O
but	O
they	O
strongly	O
suggest	O
that	O
the	O
proliferative	O
signals	O
associated	O
with	O
the	O
onset	O
of	O
cell	O
division	O
are	O
linked	O
to	O
the	O
form	O
of	O
endocytic	O
transport	O
required	O
by	O
HPV	B-OG
for	O
a	O
successful	O
virus	B-DS
infection	I-DS
.	O

Which	O
signalling	O
pathways	O
,	O
or	O
types	O
of	O
endocytic	O
transport	O
,	O
are	O
so	O
linked	O
to	O
the	O
cell	O
cycle	O
and	O
virus	B-OG
entry	O
will	O
be	O
a	O
subject	O
of	O
future	O
study	O
.	O

Finally	O
these	O
studies	O
also	O
highlight	O
that	O
HPV	B-OG
-	I-OG
16	I-OG
PsVs	O
are	O
remarkably	O
stable	O
when	O
bound	O
to	O
their	O
target	O
cell	O
,	O
and	O
can	O
remain	O
infectious	O
for	O
several	O
weeks	O
.	O

Nonetheless	O
during	O
the	O
whole	O
of	O
this	O
time	O
the	O
virus	B-OG
is	O
highly	O
vulnerable	O
to	O
neutralising	O
antibodies	B-GP
.	O

This	O
suggests	O
that	O
,	O
from	O
a	O
virological	O
perspective	O
,	O
residing	O
in	O
an	O
internal	O
vesicular	O
compartment	O
for	O
extended	O
periods	O
of	O
time	O
is	O
not	O
compatible	O
with	O
virus	B-OG
survival	O
,	O
but	O
rather	O
,	O
being	O
bound	O
to	O
the	O
cell	O
surface	O
and	O
primed	O
to	O
enter	O
the	O
cell	O
upon	O
the	O
receipt	O
of	O
appropriate	O
growth	O
-	O
promoting	O
signals	O
is	O
most	O
favourable	O
.	O

Electronic	O
supplementary	O
material	O

Supplementary	O
informations	O

Justyna	O
Broniarczyk	O
and	O
Nadja	O
Ring	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Electronic	O
supplementary	O
material	O

Supplementary	O
information	O
accompanies	O
this	O
paper	O
at	O
10	O
.	O
1038	O
/	O
s41598	O
-	O
017	O
-	O
18809	O
-	O
6	O
.	O

Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

